<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: businesses", fill: "#d70040"},
{source: "2: businesses", target: "2: significantly", fill: "#d70040"},
{source: "2: significantly", target: "2: pharmaceutical", fill: "#d70040"},
{source: "2: pharmaceutical", target: "2: biotechnology", fill: "#d70040"},
{source: "2: biotechnology", target: "2: activities", fill: "#d70040"},
{source: "2: businesses", target: "3: significant investment", fill: "#f7f"},
{source: "3: significant investment", target: "3: facilities", fill: "#f7f"},
{source: "3: facilities", target: "3: development", fill: "#f7f"},
{source: "3: development", target: "3: pharmaceutical", fill: "#f7f"},
{source: "3: pharmaceutical", target: "3: biotechnology companies look", fill: "#f7f"},
{source: "3: significant investment", target: "4: resources on", fill: "#7b68ee"},
{source: "4: resources on", target: "4: competency", fill: "#7b68ee"},
{source: "4: competency", target: "4: drug discovery while", fill: "#7b68ee"},
{source: "4: drug discovery while", target: "4: outsourced services from", fill: "#7b68ee"},
{source: "4: outsourced services from", target: "4: Charles River", fill: "#7b68ee"},
{source: "4: resources on", target: "5: next several years", fill: "#e6e8fa"},
{source: "5: next several years", target: "5: activity could", fill: "#e6e8fa"},
{source: "5: activity could", target: "5: adversely affect", fill: "#e6e8fa"},
{source: "5: adversely affect", target: "5: financial condition", fill: "#e6e8fa"},
{source: "5: financial condition", target: "5: operations", fill: "#e6e8fa"},
{source: "5: next several years", target: "14: adversely affected", fill: "#3d2b1f"},
{source: "14: adversely affected", target: "14: significant decrease", fill: "#3d2b1f"},
{source: "14: significant decrease", target: "14: life sciences research", fill: "#3d2b1f"},
{source: "14: life sciences research", target: "14: development", fill: "#3d2b1f"},
{source: "14: development", target: "14: expenditures by pharmaceutical", fill: "#3d2b1f"},
{source: "14: expenditures by pharmaceutical", target: "14: biotechnology companies as well as by", fill: "#3d2b1f"},
{source: "14: biotechnology companies as well as by", target: "14: academic institutions government laboratories", fill: "#3d2b1f"},
{source: "14: academic institutions government laboratories", target: "14: private foundations", fill: "#3d2b1f"},
{source: "14: adversely affected", target: "18: government", fill: "#8e4585"},
{source: "18: government", target: "18: budgetary", fill: "#8e4585"},
{source: "18: government", target: "31: This ", fill: "#bf4f51"},
{source: "31: This ", target: "31: adversely", fill: "#bf4f51"},
{source: "31: adversely", target: "31: development", fill: "#bf4f51"},
{source: "31: development", target: "31: expenditures", fill: "#bf4f51"},
{source: "31: expenditures", target: "31: pharmaceutical", fill: "#bf4f51"},
{source: "31: pharmaceutical", target: "31: biotechnology companies which could", fill: "#bf4f51"},
{source: "31: biotechnology companies which could", target: "31: opportunities available", fill: "#bf4f51"},
{source: "31: This ", target: "71: participants", fill: "#b0e0e6"},
{source: "71: participants", target: "71: connection with", fill: "#b0e0e6"},
{source: "71: connection with", target: "71: clinical trial", fill: "#b0e0e6"},
{source: "71: clinical trial", target: "71: trial could", fill: "#b0e0e6"},
{source: "71: trial could", target: "71: trial at no further cost", fill: "#b0e0e6"},
{source: "71: trial at no further cost", target: "71: customer but at", fill: "#b0e0e6"},
{source: "71: participants", target: "93: Impairment ", fill: "#bdb76b"},
{source: "93: Impairment ", target: "93: acquisition", fill: "#bdb76b"},
{source: "93: acquisition", target: "93: of Inveresk ", fill: "#bdb76b"},
{source: "93: of Inveresk ", target: "93: adversely impact future", fill: "#bdb76b"},
{source: "93: adversely impact future", target: "93: operations", fill: "#bdb76b"},
{source: "93: Impairment ", target: "START_HERE", fill: "#bdb76b"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Business">Business</a></td>
      <td>Business is the activity of making one's living or making money by producing or buying and selling products (such as goods and services). It is also "any activity or enterprise entered into for profit."Having a business name does not separate the business entity from the owner, which means that the owner of the business is responsible and liable for debts incurred by the business.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medication">Medication</a></td>
      <td>Meditation is a practice in which an individual uses a technique – such as mindfulness, or focusing the mind on a particular object, thought, or activity – to train attention and awareness, and achieve a mentally clear and emotionally calm and stable state.Meditation  is practiced in numerous religious traditions. The earliest records of meditation (dhyana) are found in the Upanishads of Hindu philosophy, and meditation plays a salient role in the contemplative repertoire of Buddhism and Hinduism.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutics">Pharmaceutics</a></td>
      <td>Pharmaceutics is the discipline of pharmacy that deals with the process of turning a new chemical entity (NCE) or old drugs into a medication to be used safely and effectively by patients.  It is also called the science of dosage form design.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_industry">Pharmaceutical industry</a></td>
      <td>The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered to patients (or self-administered), with the aim to cure them, vaccinate them, or alleviate symptoms.  Pharmaceutical companies may deal in generic or brand medications and medical devices.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Teva_Pharmaceuticals">Teva Pharmaceuticals</a></td>
      <td>Teva Pharmaceutical Industries Ltd. (also known as Teva Pharmaceuticals) is an Israeli multinational pharmaceutical company with headquarters in Petah Tikva, Israel.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_code">Pharmaceutical code</a></td>
      <td>Pharmaceutical codes are used in medical classification to uniquely identify medication. They may uniquely identify an active ingredient, drug system (including inactive ingredients and time-release agents) in general, or a specific pharmaceutical product from a specific manufacturer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sun_Pharma">Sun Pharma</a></td>
      <td>Sun Pharmaceutical Industries Limited (d/b/a Sun Pharma) is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs)  in more than 100 countries across the globe. It is largest pharma company in India and the fourth largest specialty generic pharmaceutical company in the world, with a total revenue of over US$4.5 billion as of June 2021.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Janssen_Pharmaceuticals">Janssen Pharmaceuticals</a></td>
      <td>Janssen Pharmaceuticals is a pharmaceutical company headquartered in Beerse, Belgium, and wholly-owned by Johnson &amp; Johnson. It was founded in 1953 by Paul Janssen.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_lobby">Pharmaceutical lobby</a></td>
      <td>The pharmaceutical lobby refers to the representatives of pharmaceutical drug and biomedicine companies who engage in lobbying in favour of pharmaceutical companies and their products.\n\n\n== Political influence in the United States ==\nThe largest pharmaceutical companies and their two trade groups, Pharmaceutical Research and Manufacturers of America (PhRMA) and Biotechnology Innovation Organization, lobbied on at least 1,600 pieces of legislation between 1998 and 2004.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Child_development">Child development</a></td>
      <td>Child development involves the biological, psychological and emotional changes that occur in human beings between birth and the conclusion of adolescence. Childhood is divided into 3 stages of life which include early childhood, middle childhood, late childhood ( preadolescence).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Drug_design">Drug design</a></td>
      <td>Drug design, often referred to as rational drug design or simply rational design, is the inventive process of finding new medications based on the knowledge of a biological target. The drug is most commonly an organic small molecule that activates or inhibits the function of a biomolecule such as a protein, which in turn results in a therapeutic benefit to the patient.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Life_Insurance_Corporation">Life Insurance Corporation</a></td>
      <td>Life Insurance Corporation of India (LIC) is an Indian statutory insurance and investment corporation headquartered in the city of Mumbai, India. It is under the ownership of Government of India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Defence_mechanism">Defence mechanism</a></td>
      <td>In psychoanalytic theory, a defence mechanism (American English: defense mechanism), is an unconscious psychological operation that functions to protect a person from anxiety-producing thoughts and feelings related to internal conflicts and outer stressors.Defence mechanisms may result in healthy or unhealthy consequences depending on the circumstances and frequency with which the mechanism is used. Defence mechanisms (German: Abwehrmechanismen) are psychological strategies brought into play by the unconscious mind to manipulate, deny, or distort reality in order to defend against feelings of anxiety and unacceptable impulses and to maintain one's self-schema or other schemas.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Ivor_Montagu">Ivor Montagu</a></td>
      <td>Ivor Goldsmid Samuel Montagu (23 April 1904, in Kensington, London – 5 November 1984, in Watford) was an English filmmaker, screenwriter, producer, film critic, writer, table tennis player, and Communist activist in the 1930s. He helped to develop a lively intellectual film culture in Britain during the interwar years, and was also the founder of the International Table Tennis Federation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/North_American_Free_Trade_Agreement">North American Free Trade Agreement</a></td>
      <td>The North American Free Trade Agreement (NAFTA ; Spanish: Tratado de Libre Comercio de América del Norte, TLCAN; French: Accord de libre-échange nord-américain, ALÉNA) was an agreement signed by Canada, Mexico, and the United States that created a trilateral trade bloc in North America. The agreement came into force on January 1, 1994, and superseded the 1988 Canada–United States Free Trade Agreement between the United States and Canada.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Government">Government</a></td>
      <td>A government is the system or group of people governing an organized community, generally a state.\nIn the case of its broad associative definition, government normally consists of legislature, executive, and judiciary.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Federal_government_of_the_United_States">Federal government of the United States</a></td>
      <td>The federal government of the United States (U.S. federal government or U.S. government) is the national government of the United States, a federal republic in North America, composed of 50 states, a city within a federal district (the city of Washington in the District of Columbia, where the entire federal government is based), five major self-governing territories and several island possessions. The federal government is composed of three distinct branches: legislative, executive, and judicial, whose powers are vested by the U.S. Constitution in the Congress, the president and the federal courts, respectively.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Government_agency">Government agency</a></td>
      <td>A government or state agency, sometimes an appointed commission, is a permanent or semi-permanent organization in the machinery of government that is responsible for the oversight and administration of specific functions, such as an administration. There is a notable variety of agency types.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Military_government">Military government</a></td>
      <td>A military government is generally any government that is administered by military forces, whether or not this government is legal under the laws of the jurisdiction at issue, and whether this government is formed by natives or by an occupying power. It is usually carried out by military workers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Government_of_Canada">Government of Canada</a></td>
      <td>The government of Canada (French: gouvernement du Canada) is the body responsible for the federal administration of Canada. A constitutional monarchy, the Crown is the corporation sole, assuming distinct roles: the executive, as the Crown-in-Council; the legislature, as the Crown-in-Parliament; and the courts, as the Crown-on-the-Bench.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adverse_possession">Adverse possession</a></td>
      <td>Adverse possession, sometimes colloquially described as "squatter's rights", is a legal principle in the Anglo-American common law under which a person who does not have legal title to a piece of property—usually land (real property)—may acquire legal ownership based on continuous possession or occupation of the property without the permission (licence) of its legal owner. The possession by a person is not adverse if they are in possession as a tenant or licensee of the legal owner.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Sicilian_Connection">The Sicilian Connection</a></td>
      <td>The Sicilian Connection (Italian: Afyon oppio, French: Action héroïne, also known as The Opium Connection and La filière) is a 1972 Italian-French crime-thriller film directed by Ferdinando Baldi.\n\n\n== Plot ==\nThe Italian-American Joseph Coppola wants to start trafficking drugs from Turkey to the United States and calls for the support of the Sicilian Mafia, who would  protect him from the Marseilles Clan.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Continental_Connection">Continental Connection</a></td>
      <td>Continental Connection was a brand name under which several commuter airline carriers and their holding companies operated services marketed exclusively by Continental Airlines. As such, all Continental Connection banner carrier services were operated primarily with turboprop aircraft in contrast to Continental Express, whose flights were operated by Continental's regional jet partners, ExpressJet Airlines and Chautauqua Airlines.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Connection_pool">Connection pool</a></td>
      <td>In software engineering, a connection pool is a cache of database connections maintained so that the connections can be reused when future requests to the database are required.\nConnection pools are used to enhance the performance of executing commands on a database.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mothership_Connection">Mothership Connection</a></td>
      <td>Mothership Connection is the fourth album by American funk band Parliament, released on December 15, 1975 on Casablanca Records. This concept album is often rated among the best Parliament-Funkadelic releases, and was the first to feature horn players Maceo Parker and Fred Wesley, who had previously backed James Brown in the J.B.'s.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Loud_Connection">Loud Connection</a></td>
      <td>Loud Connection (Russian: Громкая связь, romanized: Gromkaya svyaz) is a 2019 Russian comedy film directed by Aleksey Nuzhnyy. It is a remake of the 2016 Italian film\nPerfect Strangers (2016).</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>CHARLES RIVER LABORATORIES INTERNATIONAL INC      Item 1A                Risk Factors       Risks Related to Our Business and Industry       Set forth below and elsewhere in this Form 10-K and in other <font color="blue">documents</font> we     file  with the SEC are risks and <font color="blue">uncertainties</font> that could cause actual     results  to  differ  <font color="blue">materially</font>  from  the results contemplated by the     forward-looking statements contained in this Form 10-K       The  outsourcing  trend in the preclinical and <font color="blue">clinical stages</font> of drug     <font color="blue">discovery</font> and <font color="blue">development</font> may decrease, <font color="blue">which could</font> slow our growth</td>
    </tr>
    <tr>
      <td>Over  the  past several years, some areas of our <font color="blue">businesses</font> have grown     <font color="blue"><font color="blue">significant</font>ly</font>  as  a  result  of  the  increase  in <font color="blue">pharmaceutical</font> and     <font color="blue">bio<font color="blue">technology</font></font> companies outsourcing their preclinical and clinical research     support <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We believe that due to the <font color="blue"><font color="blue">significant</font> investment</font> in     <font color="blue">facilities</font>   and  personnel  required  to  support  drug  <font color="blue">development</font>,     <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> companies look to outsource some or all of     those services</td>
    </tr>
    <tr>
      <td>By doing so, they can focus their <font color="blue">resources on</font> their core     <font color="blue">competency</font> of drug <font color="blue">discovery</font>, while obtaining the <font color="blue">outsourced services from</font> a     full-service provider like <font color="blue">Charles River</font></td>
    </tr>
    <tr>
      <td>While industry analysts expect the     outsourcing trend to continue for the <font color="blue">next several years</font>, a decrease in     preclinical  and/or  clinical  outsourcing  <font color="blue">activity could</font> result in a     diminished  growth  rate  in  the sales of one or more of our expected     higher-growth areas and <font color="blue"><font color="blue">adversely</font> affect</font> our <font color="blue">financial condition</font> and results     of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Furthermore, our <font color="blue">customer contracts</font> are <font color="blue">generally terminable</font>     on  little  or  no notice</td>
    </tr>
    <tr>
      <td><font color="blue">Termination </font>of a large contract or multiple     contracts could <font color="blue"><font color="blue">adversely</font> affect</font> our sales and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> and financial results could be <font color="blue"><font color="blue">significant</font>ly</font> affected by the     above-mentioned risks</td>
    </tr>
    <tr>
      <td>A  reduction in research and <font color="blue">development</font> budgets at <font color="blue">pharmaceutical</font> and     <font color="blue">bio<font color="blue">technology</font></font> companies may <font color="blue"><font color="blue">adversely</font> affect</font> our business</td>
    </tr>
    <tr>
      <td>Our  customers include <font color="blue">researchers</font> at <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font>     companies</td>
    </tr>
    <tr>
      <td>Our ability to continue to grow and win new business is <font color="blue">dependent</font>     in large part upon the ability and <font color="blue">willingness</font> of the <font color="blue">pharmaceutical</font> and     <font color="blue">bio<font color="blue">technology</font></font> industries to continue to <font color="blue">spend on research</font> and <font color="blue">development</font>     and to outsource the products and services we provide</td>
    </tr>
    <tr>
      <td><font color="blue">Fluctuations </font>in the     research  and  <font color="blue">development</font>  budgets  of  these  <font color="blue">researchers</font>  and their     <font color="blue"><font color="blue">organization</font>s could</font> have a <font color="blue">significant</font> effect on the demand for our products     and services</td>
    </tr>
    <tr>
      <td>Research and <font color="blue">development</font> budgets fluctuate due to changes in     available resources, mergers       13     ______________________________________________________________________       of <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> companies, spending priorities and     <font color="blue">institutional</font> <font color="blue">budgetary</font> policies</td>
    </tr>
    <tr>
      <td>Our business could be <font color="blue"><font color="blue">adversely</font> affect</font>ed     by  any <font color="blue">significant</font> decrease in <font color="blue">life sciences research</font> and <font color="blue">development</font>     <font color="blue">expenditures</font> by <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> companies, as well as by     <font color="blue">academic institutions</font>, <font color="blue">government</font> laboratories or <font color="blue">private foundations</font></td>
    </tr>
    <tr>
      <td>Similarly, <font color="blue">economic factors</font> and industry trends that affect our clients in     these <font color="blue">industries also affect</font> our business</td>
    </tr>
    <tr>
      <td>A reduction or delay in <font color="blue"><font color="blue">government</font> funding</font> of research and <font color="blue">development</font> may     <font color="blue"><font color="blue">adversely</font> affect</font> our business</td>
    </tr>
    <tr>
      <td>A portion of net sales in our RMS segment is <font color="blue">derived from customers at</font>     <font color="blue">academic institutions</font> and <font color="blue">research laboratories whose funding</font> is partially     <font color="blue">dependent</font> on both the level and timing of <font color="blue">funding from <font color="blue">government</font> sources</font>,     such as the US National Institutes of Health (NIH) and similar domestic     and  <font color="blue">international</font> agencies</td>
    </tr>
    <tr>
      <td>Although the level of <font color="blue">government</font> research     funding has increased during the past several years the size of <font color="blue">budgetary</font>     increases  has  recently  declined</td>
    </tr>
    <tr>
      <td><font color="blue">Government </font>funding of research and     <font color="blue">development</font>  is  subject to the political process, which is <font color="blue">inherently</font>     unpredictable</td>
    </tr>
    <tr>
      <td>Our sales may be <font color="blue"><font color="blue">adversely</font> affect</font>ed if our <font color="blue">customers delay</font>     purchases  as  a  result  of <font color="blue">uncertainties</font> surrounding the approval of     <font color="blue">government</font>  budget  proposals</td>
    </tr>
    <tr>
      <td>Also, <font color="blue">government</font> proposals to reduce or     eliminate <font color="blue">budgetary</font> deficits have sometimes included <font color="blue">reduced allocations</font> to     the NIH and other <font color="blue">government</font> agencies that <font color="blue">fund research</font> and <font color="blue">development</font>     <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>A  reduction  in  <font color="blue"><font color="blue">government</font> funding</font> for the NIH or other     <font color="blue">government</font> research agencies could <font color="blue"><font color="blue">adversely</font> affect</font> our business and our     financial results</td>
    </tr>
    <tr>
      <td><font color="blue">Changes  </font>in  <font color="blue">government</font>  regulation  or  in  practices relating to the     <font color="blue">pharmaceutical</font> or <font color="blue">biotechnological industries</font>, including <font color="blue">potential health</font>     <font color="blue">care reform could decrease</font> the need for the services we provide</td>
    </tr>
    <tr>
      <td><font color="blue">Governmental </font><font color="blue">agencies throughout</font> the world, but <font color="blue">particularly</font> in the United     States,  strictly  regulate the drug <font color="blue">development</font> process</td>
    </tr>
    <tr>
      <td>Our business     involves helping <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> companies, among others,     navigate the <font color="blue"><font color="blue">regulatory</font> drug approval process</font></td>
    </tr>
    <tr>
      <td>Changes in <font color="blue">regulations</font>, such     as a <font color="blue">relaxation</font> in <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font> or the <font color="blue">introduction</font> of simplified     <font color="blue">drug approval procedures</font>, or an increase in <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font> that we     have <font color="blue"><font color="blue">difficult</font>y</font> satisfying or that make our services less <font color="blue">competitive</font>, could     eliminate or <font color="blue">substantially reduce</font> the demand for our services</td>
    </tr>
    <tr>
      <td>In <font color="blue">recent years</font> the <font color="blue"><font color="blue">United States</font> Congress </font>and state <font color="blue">legislatures</font> have     considered various types of health care reform in order to control growing     health care costs</td>
    </tr>
    <tr>
      <td>We are unable to predict what <font color="blue">legislative proposals will</font>     be adopted in the future, if any</td>
    </tr>
    <tr>
      <td>Similar <font color="blue">reform movements</font> have occurred in     <font color="blue">Europe and Asia</font></td>
    </tr>
    <tr>
      <td><font color="blue">Implementation </font>of health care reform <font color="blue">legislation</font> that contains costs could     limit the profits that can be made from the <font color="blue">development</font> of new drugs</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font>could  <font color="blue">adversely</font>  affect  research  and  <font color="blue">development</font>  <font color="blue">expenditures</font>  by     <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> companies, <font color="blue">which could</font> in turn decrease the     business <font color="blue">opportunities available</font> to us both in the united States and abroad</td>
    </tr>
    <tr>
      <td>In  addition,  new laws or <font color="blue">regulations</font> may create a risk of <font color="blue">liability</font>,     increase our costs or limit our <font color="blue">service offerings</font></td>
    </tr>
    <tr>
      <td>Our standard <font color="blue">customer agreements contain liberal <font color="blue">termination</font></font> and service     reduction provisions, which may result in <font color="blue">less contract revenue than</font> we     anticipate</td>
    </tr>
    <tr>
      <td>Generally, our <font color="blue">agreements with</font> our customers provide that the customers can     terminate  the  agreements  or  reduce the scope of <font color="blue">services under</font> the     <font color="blue">agreements with</font> little or no notice</td>
    </tr>
    <tr>
      <td><font color="blue">Customers </font>may elect to terminate their     <font color="blue">agreements with</font> us for <font color="blue">various reasons</font>, including: the products being tested     fails to satisfy safety <font color="blue">requirements</font>; unexpected or <font color="blue">undesired study</font> results;     <font color="blue">production problems</font> resulting in shortages of the drug being tested; the     customer’s decision to forego or terminate a <font color="blue">particular study</font>; or the loss     of funding for the <font color="blue">particular research study</font></td>
    </tr>
    <tr>
      <td>If a customer terminates a     contract with us, we are entitled under the terms of the contract to receive     <font color="blue">revenue earned</font> to <font color="blue">date as well as certain</font> other costs and, in some cases,     penalties</td>
    </tr>
    <tr>
      <td><font color="blue">Cancellation </font>of a large contract or <font color="blue">proximate <font color="blue">cancellation</font></font> of     multiple       14     ______________________________________________________________________       contracts could <font color="blue">materially</font> <font color="blue"><font color="blue">adversely</font> affect</font> the <font color="blue">Preclinical or Clinical     </font>segments’  business and, therefore, may <font color="blue"><font color="blue">adversely</font> affect</font> our operating     results</td>
    </tr>
    <tr>
      <td><font color="blue">Contaminations </font>in our animal <font color="blue">populations</font> can damage our inventory, harm our     reputation for contaminant-free production and result in <font color="blue">decreased sales</font></td>
    </tr>
    <tr>
      <td>Our  research  models and <font color="blue">fertile chicken eggs must</font> be free of certain     adventious, infectious agents such as certain viruses and bacteria because     the presence of these <font color="blue">contaminants</font> can distort or compromise the quality of     research results and could <font color="blue">adversely</font> impact human or <font color="blue">animal health</font></td>
    </tr>
    <tr>
      <td>The     presence of these infectious agents in our animal production <font color="blue">facilities</font> and     certain service <font color="blue">operations</font> could disrupt our contaminant-free research model     and  fertile  <font color="blue">egg production as well as</font> our animal services <font color="blue">businesses</font>     including transgenic services, harm our reputation for contaminant-free     production and result in <font color="blue">decreased sales</font></td>
    </tr>
    <tr>
      <td><font color="blue">Contaminations </font>typically require cleaning up, renovating, disinfecting and     <font color="blue">restarting production</font> in the <font color="blue">contaminated barrier room</font> or <font color="blue">poultry house</font></td>
    </tr>
    <tr>
      <td>This clean-up results in inventory loss, clean-up and start-up costs, and     <font color="blue">reduced sales as</font> a result of <font color="blue">lost customer orders</font> and credits for prior     shipments</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">contaminations</font> expose us to risks that customers     will  request  <font color="blue">compensation</font>  for  damages in excess of our <font color="blue">contractual</font>     <font color="blue">indemnification</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">contaminations</font> are <font color="blue">unanticipated</font> and     <font color="blue">difficult</font> to predict and could <font color="blue">adversely</font> impact our financial results</td>
    </tr>
    <tr>
      <td>We     have  made <font color="blue">significant</font> capital <font color="blue">expenditures</font> designed to strengthen our     <font color="blue">biosecurity</font> and have <font color="blue"><font color="blue">significant</font>ly</font> improved our operating procedures to     protect against such <font color="blue">contaminations</font>, however, <font color="blue">contaminations</font> may still     occur</td>
    </tr>
    <tr>
      <td>Our business is subject to risks relating to operating <font color="blue">international</font>ly</td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> part of our net sales is derived from <font color="blue">operations</font> outside the     <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">international</font> revenues, which include <font color="blue">revenues from</font> our     non-US subsidiaries, represented  48dtta5prca of our <font color="blue">total net sales</font> in 2005,     36dtta3prca of our <font color="blue">total net sales</font> in 2004, and 30dtta8prca in 2003</td>
    </tr>
    <tr>
      <td>We expect that     <font color="blue">international</font> revenues will continue to account for a <font color="blue">significant</font> percentage     of our revenues for the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>There are a number of risks     associated with our <font color="blue">international</font> business, including:       ·       foreign currencies we receive for <font color="blue">sales outside</font> the <font color="blue">United States</font>     could be subject to unfavorable exchange rates with the US dollar and     reduce the amount of revenue that we recognize;       ·       <font color="blue">general economic</font> and <font color="blue">political <font color="blue">conditions</font></font> in the markets in which we     operate;       ·       potential <font color="blue">international</font> conflicts, including terrorist acts;       ·        potential  increased  costs  associated  <font color="blue">with overlapping tax</font>     structures;       ·       <font color="blue">potential trade <font color="blue">restrictions</font></font> and <font color="blue">exchange controls</font>;       ·       <font color="blue">difficult</font>ies and <font color="blue">costs associated with staffing</font> and <font color="blue">managing foreign</font>     <font color="blue">operations</font>, including risks of violations of <font color="blue">local laws</font> or the US Foreign     Corrupt Practices Act <font color="blue">by employees oversees</font>;       ·       unexpected changes in <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font>;       ·       the <font color="blue">difficult</font>ies of <font color="blue">compliance with</font> a wide variety of <font color="blue">foreign laws</font>     and <font color="blue">regulations</font>;       ·        unfavorable  labor  <font color="blue">regulations</font>, including <font color="blue">specifically</font> those     applicable to our European <font color="blue">operations</font>;       ·       <font color="blue">longer accounts receivable cycles</font> in <font color="blue">certain foreign countries</font>; and       ·       import and export licensing <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>15     ______________________________________________________________________       Negative <font color="blue">attention from special interest groups may impair</font> our business</td>
    </tr>
    <tr>
      <td>The products and <font color="blue">services which</font> we provide our customers are essential  to     the drug <font color="blue">discovery</font> and <font color="blue">development</font> process, and are <font color="blue">almost universally</font>     mandated  by  law</td>
    </tr>
    <tr>
      <td>Notwithstanding,  <font color="blue">certain special interests groups</font>     <font color="blue">categorically</font> object to the use of animals for <font color="blue">valid research purposes</font></td>
    </tr>
    <tr>
      <td>Historically, our core research model <font color="blue">activities</font> with rats, mice and other     rodents have not been the subject of <font color="blue">animal rights media attention</font></td>
    </tr>
    <tr>
      <td>However,     research <font color="blue">activities</font> with animals have been the subject of <font color="blue">adverse attention</font>,     impacting  our industry</td>
    </tr>
    <tr>
      <td>This has included occasional, but infrequent,     on-site demonstrations at <font color="blue">facilities</font> operated by us</td>
    </tr>
    <tr>
      <td>Any <font color="blue">negative attention</font>     or <font color="blue">threats directed against</font> our animal research <font color="blue">activities</font> in the future     <font color="blue">could impair</font> our ability to operate our business <font color="blue">efficiently</font></td>
    </tr>
    <tr>
      <td>In addition,     if <font color="blue"><font color="blue">regulatory</font> authorities</font> were to mandate a <font color="blue">significant</font> reduction in safety     testing procedures which utilize laboratory animals (as has been advocated     <font color="blue">by certain groups</font>), our business could be <font color="blue">materially</font> <font color="blue">adversely</font> effected</td>
    </tr>
    <tr>
      <td>Several of our product and <font color="blue">service offerings</font> are <font color="blue">dependent</font> on a limited     source of supply, which if <font color="blue">interrupted</font> could <font color="blue"><font color="blue">adversely</font> affect</font> our business</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> a limited <font color="blue">international</font> source of supply of large <font color="blue">animal models</font>     required  in  our  product and <font color="blue">service offerings</font></td>
    </tr>
    <tr>
      <td><font color="blue">Disruptions </font>to their     continued supply may arise from colony <font color="blue">fertility</font> and health problems, export     or  import  <font color="blue">restrictions</font>  or <font color="blue">embargoes</font>, foreign <font color="blue">government</font> or economic     <font color="blue">instability</font>, severe weather <font color="blue">conditions</font>, <font color="blue"><font color="blue">disruption</font>s</font> to the <font color="blue">air travel system</font>     or <font color="blue">contract disputes</font> or <font color="blue"><font color="blue">disruption</font>s</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">disruption</font> of <font color="blue">supply <font color="blue">could harm</font></font> our     business if we <font color="blue">cannot remove</font> the <font color="blue">disruption</font> or are unable to secure an     <font color="blue">alternative</font> or <font color="blue">secondary supply source on comparable commercial terms</font></td>
    </tr>
    <tr>
      <td>We may be unable to <font color="blue">build out</font> our <font color="blue">facilities</font> as anticipated</td>
    </tr>
    <tr>
      <td>To  take advantage of our customers’ continued growing demand for drug     <font color="blue">discovery</font> and <font color="blue">development</font> services, including <font color="blue">increased strategic focus on</font>     <font color="blue">outsourcing services</font> and programs, we are engaged in a substantial <font color="blue">capacity</font>     expansion  program, with approximately dlra175-dlra200 million allocated for     capital <font color="blue">expenditures</font> for 2006</td>
    </tr>
    <tr>
      <td>Included in this build-out are two US     Preclinical Services <font color="blue">facilities</font>—one in <font color="blue">Massachusetts </font>scheduled to be online     by the end of 2006 and one in Nevada scheduled for 2007—and an expansion of     our <font color="blue">RMS California </font><font color="blue">capabilities scheduled</font> to <font color="blue">partially open</font> in the fourth     quarter of 2006</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that any or all of these <font color="blue">facilities</font>     will be <font color="blue">constructed on</font> the anticipated timetable or on budget</td>
    </tr>
    <tr>
      <td>Any material     delay in bringing these <font color="blue">facilities</font> on-line, or substantial increase in costs     to complete these <font color="blue">facilities</font>, could <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affect</font> us</td>
    </tr>
    <tr>
      <td>Any  failure  by us to comply with existing <font color="blue">regulations</font> <font color="blue">could harm</font> our     reputation and operating results</td>
    </tr>
    <tr>
      <td>Any <font color="blue">failure on</font> our part to comply with existing <font color="blue">regulations</font> could result in     the <font color="blue">termination</font> of <font color="blue">ongoing research</font> or the <font color="blue">disqualification</font> of data for     submission to <font color="blue"><font color="blue">regulatory</font> authorities</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">could harm</font> our reputation, our     prospects for future work and our operating results</td>
    </tr>
    <tr>
      <td>For example, if we were     to  fail  to  verify  that  informed  consent is obtained from patient     <font color="blue">participants</font> in <font color="blue">connection with</font> a particular Phase I <font color="blue">clinical trial</font>, the     data  collected  from that <font color="blue">trial could</font> be disqualified and we might be     required  to redo the <font color="blue">trial at no further cost</font> to our customer, but at     substantial cost to us</td>
    </tr>
    <tr>
      <td>Furthermore, the issuance of a notice from the FDA     <font color="blue">based on</font> a finding of a material <font color="blue">violation by us</font> of good <font color="blue">clinical practice</font>,     good <font color="blue">laboratory practice</font> or good manufacturing practice <font color="blue">requirements</font> could     <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affect</font> us</td>
    </tr>
    <tr>
      <td>The drug <font color="blue">discovery</font> and <font color="blue">development</font> services industry is <font color="blue">highly <font color="blue">competitive</font></font></td>
    </tr>
    <tr>
      <td>We  often  compete for business not only with other drug <font color="blue">discovery</font> and     <font color="blue">development</font> companies, but also with internal <font color="blue">discovery</font> and <font color="blue">development</font>     <font color="blue">departments within</font> our clients, who are often large <font color="blue">pharmaceutical</font> and     <font color="blue">bio<font color="blue">technology</font></font> companies with greater resources than ours</td>
    </tr>
    <tr>
      <td>We <font color="blue">also compete</font>     <font color="blue">with universities</font> and <font color="blue">teaching hospitals</font></td>
    </tr>
    <tr>
      <td>If       16     ______________________________________________________________________       we  do  not  <font color="blue">compete successfully</font>, our business will suffer</td>
    </tr>
    <tr>
      <td><font color="blue">Increased     </font><font color="blue">competition</font> might lead to price and other forms of <font color="blue">competition</font> that might     <font color="blue">adversely</font>  affect  our  operating  results</td>
    </tr>
    <tr>
      <td>As a result of <font color="blue">competitive</font>     pressures, the drug <font color="blue">discovery</font> and <font color="blue">development</font> services industry has been     <font color="blue">consolidating</font></td>
    </tr>
    <tr>
      <td>This trend is likely to produce more <font color="blue">competition</font> among the     <font color="blue">larger companies</font> for <font color="blue">both clients</font> and <font color="blue"><font color="blue">acquisition</font> candidates</font></td>
    </tr>
    <tr>
      <td>In addition,     for some of our business segments, there are <font color="blue">few barriers</font> to entry for     <font color="blue">smaller specialized companies</font> considering entering the industry</td>
    </tr>
    <tr>
      <td>Because of     their size and focus, these companies might compete <font color="blue">effectively</font> against     <font color="blue">larger companies</font> such as us, <font color="blue">which could</font> have a material adverse <font color="blue">impact on</font>     our business</td>
    </tr>
    <tr>
      <td>Tax benefits we expect to be available in the <font color="blue">future may</font> be subject to     challenge</td>
    </tr>
    <tr>
      <td>In <font color="blue">connection with</font> our 1999 recapitalization, our then current shareholders,     <font color="blue">CRL Acquisition </font>LLC (CRL Acquisition) and Bausch &amp; Lomb Incorporated (B&amp;L),     made a <font color="blue">joint election intended</font> to <font color="blue">permit us</font> to increase the depreciable and     <font color="blue">amortizable tax basis</font> in our assets for federal income <font color="blue">tax purposes</font>, thereby     <font color="blue">providing us with</font> expected <font color="blue"><font color="blue">future tax</font> benefits</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">connection with</font> our     <font color="blue">initial public offering</font> in 2000, <font color="blue">CRL Acquisition </font>reorganized, terminated its     <font color="blue">existence as</font> a <font color="blue">corporation</font> for <font color="blue">tax purposes</font> and <font color="blue">distributed</font> a substantial     portion of its stock to its members</td>
    </tr>
    <tr>
      <td>We believe that the <font color="blue">re<font color="blue">organization</font></font> and     <font color="blue"><font color="blue">liquidating</font> <font color="blue">distribution should</font></font> not have any <font color="blue">impact on</font> the election for     federal income <font color="blue">tax purposes</font></td>
    </tr>
    <tr>
      <td>However, it is possible that the Internal     Revenue Service (IRS) may contend that this <font color="blue">re<font color="blue">organization</font></font> and <font color="blue">liquidating</font>     <font color="blue">distribution should</font> be <font color="blue">integrated with</font> our <font color="blue">original recapitalization</font></td>
    </tr>
    <tr>
      <td>If the     IRS were to be <font color="blue">successful with</font> this <font color="blue">contention</font>, the expected <font color="blue">future tax</font>     <font color="blue">benefits at</font> the time of the <font color="blue">recapitalization would</font> not be available and we     would be required to write off the related <font color="blue">deferred tax asset</font></td>
    </tr>
    <tr>
      <td>We could be <font color="blue"><font color="blue">adversely</font> affect</font>ed by tax law changes in the <font color="blue"><font color="blue">United Kingdom</font> </font>or     Canada</td>
    </tr>
    <tr>
      <td>We  have substantial <font color="blue">operations</font> in the <font color="blue"><font color="blue">United Kingdom</font> </font>and Canada which     <font color="blue">currently benefit from</font> favorable <font color="blue">corporate tax arrangements</font></td>
    </tr>
    <tr>
      <td>We receive     substantial tax credits in Canada from both the <font color="blue">Canadian </font>federal and <font color="blue">Quebec     </font><font color="blue">government</font>s  and  it  benefits  from  tax  credits and <font color="blue">accelerated tax</font>     <font color="blue">depreciation</font>  <font color="blue">allowances</font>  in  the <font color="blue">United Kingdom</font></td>
    </tr>
    <tr>
      <td>Any reduction in the     <font color="blue">availability</font> or amount of these tax credits or <font color="blue">allowances</font> would be likely to     have a material adverse effect on profits and <font color="blue">cash flow from either</font> or both     of our <font color="blue">Canadian </font>and <font color="blue"><font color="blue">United Kingdom</font> </font><font color="blue">operations</font>, and on our <font color="blue">effective tax</font>     rate</td>
    </tr>
    <tr>
      <td><font color="blue">Impairment  </font>of  goodwill  arising from the <font color="blue">acquisition</font> <font color="blue">of Inveresk </font>may     <font color="blue">adversely</font> impact future results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We accounted for our <font color="blue">acquisition</font> <font color="blue">of Inveresk </font>as a <font color="blue">purchase under <font color="blue">accounting</font></font>     <font color="blue">principles generally accepted</font> in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Under the purchase     method of <font color="blue">accounting</font>, the assets and <font color="blue">liabilities</font> of Inveresk, including     <font color="blue">identifiable intangible assets</font>, have <font color="blue">been recorded at</font> their <font color="blue">respective fair</font>     values as of the date the <font color="blue">acquisition</font> was completed</td>
    </tr>
    <tr>
      <td>The excess of the     <font color="blue">purchase price over</font> the <font color="blue">fair value</font> of acquired net assets and <font color="blue">liabilities</font>     was <font color="blue">recorded as goodwill</font></td>
    </tr>
    <tr>
      <td>As a result of the <font color="blue">combination</font>, we have recorded     dlra1dtta3 billion of <font color="blue">additional goodwill</font> and dlra0dtta2 billion of other intangible     assets, which are material to us</td>
    </tr>
    <tr>
      <td>The <font color="blue">goodwill will</font> not be amortized, but     will be reviewed for <font color="blue"><font color="blue">impairment</font> by us at least annually</font></td>
    </tr>
    <tr>
      <td>If the future     growth and operating results of the acquired <font color="blue">businesses</font> are not <font color="blue">as strong as</font>     anticipated, <font color="blue">goodwill may</font> be impaired</td>
    </tr>
    <tr>
      <td>Such an <font color="blue">impairment</font> charge could     <font color="blue">materially</font>  and  <font color="blue">adversely</font>  affect our operating results and financial     condition</td>
    </tr>
    <tr>
      <td>Our  exposure to exchange rate <font color="blue">fluctuations</font> could <font color="blue"><font color="blue">adversely</font> affect</font> our     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We derive a <font color="blue">significant</font> portion of our revenue from <font color="blue">operations</font> outside of     the <font color="blue">United States</font>, <font color="blue">primarily from</font> our <font color="blue">operations</font> in Canada and the United     Kingdom, where <font color="blue">significant</font> amounts of revenues and expenses are recorded in     local (non-US) currency</td>
    </tr>
    <tr>
      <td>Our <font color="blue">financial statements</font> are presented in US     dollars</td>
    </tr>
    <tr>
      <td>Accordingly, changes in currency exchange rates, <font color="blue">particularly</font>     between the <font color="blue">pound sterling</font>, the <font color="blue">Canadian </font>      17     ______________________________________________________________________       dollar, the <font color="blue">European Euro and the US </font>dollar, will cause <font color="blue">fluctuations</font> in     our reported financial results, <font color="blue">which could</font> be material</td>
    </tr>
    <tr>
      <td>In addition, our     contracts with foreign customers are <font color="blue">frequently denominated</font> in currencies     other  than  the  currency in which we <font color="blue">incur expenses</font> related to those     contracts</td>
    </tr>
    <tr>
      <td>This is <font color="blue">particularly</font> the <font color="blue">case with respect</font> to the <font color="blue">Canadian </font>    <font color="blue">operations</font> we acquired from Inveresk, where <font color="blue">contracts generally provide</font> for     invoicing clients in US dollars but its expenses are <font color="blue">generally incurred</font> in     <font color="blue">Canadian </font>dollars</td>
    </tr>
    <tr>
      <td>Where expenses are incurred in currencies other than those     in <font color="blue">which contracts</font> are priced, <font color="blue">fluctuations</font> in the <font color="blue">relative value</font> of those     currencies  could  have  a  material  adverse effect on our results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Contract <font color="blue">research services</font> create a risk of <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">contracting</font> to work on drug <font color="blue">development</font> trials, as a <font color="blue">contract research</font>     <font color="blue">organization</font> we face a range of potential <font color="blue">liabilities</font>, for example:       ·        errors  or omissions that create <font color="blue">harm during</font> a trial to study     volunteers  or after a trial to consumers of the drug after <font color="blue">regulatory</font>     approval of the drug;       ·       <font color="blue">general risks associated with</font> Phase I <font color="blue">facilities</font>, including negative     <font color="blue">consequences from</font> the <font color="blue">administration</font> of drugs to <font color="blue">clinical trial</font> <font color="blue">participants</font>     or the <font color="blue">professional malpractice</font> of Phase I <font color="blue">medical care providers</font>;       ·       errors or <font color="blue">omissions from tests conducted</font> for the <font color="blue">agrochemical</font> and     <font color="blue">food industries</font>;       ·       risks that animals in our breeding <font color="blue">facilities</font> may be <font color="blue">infected with</font>     diseases  that may be harmful and even lethal to <font color="blue">themselves</font> and humans     despite  <font color="blue">preventive measures contained</font> in our <font color="blue">company policies</font> for the     quarantine and handling of <font color="blue">imported animals</font>; and       ·        errors  and  omissions  during a trial that <font color="blue">may undermine</font> the     usefulness of a trial or data from the trial</td>
    </tr>
    <tr>
      <td>We mitigate these risks to the best of our <font color="blue">abilities through</font> our regiment of     animal testing, quarantine, and veterinary staff vigilance, through which we     seek  to control the exposure of animal related disease or <font color="blue">infections</font></td>
    </tr>
    <tr>
      <td>Nonetheless, it is impossible to <font color="blue">completely eradicate such risks</font></td>
    </tr>
    <tr>
      <td>We also contract with physicians, also referred to <font color="blue">as investigators</font>, to     conduct the <font color="blue">clinical trial</font>s to <font color="blue">test new drugs on human volunteers</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>tests  can  create a risk of <font color="blue">liability</font> for <font color="blue">personal injury</font> or death to     volunteers, resulting <font color="blue">from negative reactions</font> to the <font color="blue">drugs administered</font> or     from <font color="blue">professional malpractice</font> by third party investigators, <font color="blue">particularly</font> to     volunteers with life-threatening illnesses</td>
    </tr>
    <tr>
      <td>We believe that our risks in     this area are <font color="blue">generally reduced by</font> the <font color="blue">contract provisions <font color="blue">entitling us</font></font> to     be indemnified or <font color="blue">entitling us</font> to a <font color="blue">limitation</font> of <font color="blue">liability</font>; insurance     maintained by our clients, investigators, and by us; and various <font color="blue">regulatory</font>     <font color="blue">requirements</font> we <font color="blue">must follow</font> in <font color="blue">connection with</font> our business</td>
    </tr>
    <tr>
      <td><font color="blue">Contractual </font><font color="blue"><font color="blue">indemnification</font>s generally</font> do not protect us against <font color="blue">liability</font>     arising <font color="blue">from certain</font> of our own actions, such as negligence or <font color="blue">misconduct</font></td>
    </tr>
    <tr>
      <td>We could be <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affect</font>ed if we were required to pay     damages or bear the costs of defending any claim which is not <font color="blue">covered by</font> a     <font color="blue">contractual</font> <font color="blue">indemnification</font> provision or in the event that a party who must     <font color="blue">indemnify us</font> does not fulfill its <font color="blue"><font color="blue">indemnification</font> obligations</font> or which is     beyond the level of our <font color="blue">insurance coverage</font></td>
    </tr>
    <tr>
      <td>Furthermore, there can be no     assurance that we will be able to maintain such <font color="blue">insurance coverage</font> on terms     acceptable to us</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue"><font color="blue">attract suitable</font> investigators</font> and volunteers for our     <font color="blue">clinical trial</font>s, our business <font color="blue">might suffer</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">clinical <font color="blue">research studies</font></font> we <font color="blue">run rely upon</font> the <font color="blue">ready accessibility</font> and     <font color="blue">willing participation</font> of <font color="blue">physician investigators</font> and <font color="blue">volunteer subjects</font></td>
    </tr>
    <tr>
      <td><font color="blue">Investigators </font>are typically located at hospitals, clinics or other sites and     supervise <font color="blue">administration</font> of the study drug to <font color="blue">patients during</font> the course of     a <font color="blue">clinical trial</font></td>
    </tr>
    <tr>
      <td>Volunteer <font color="blue">subjects generally</font> include people from the     <font color="blue">communities</font> in which the studies are conducted,       18     ______________________________________________________________________       including our Phase I clinic in Edinburgh, Scotland, which to date has     provided a substantial pool of <font color="blue">potential subjects</font> for <font color="blue">research studies</font></td>
    </tr>
    <tr>
      <td>Our     clinical research <font color="blue">development</font> business could be <font color="blue"><font color="blue">adversely</font> affect</font>ed if we     were unable to <font color="blue">attract suitable</font> and <font color="blue">willing investigators</font> or <font color="blue">volunteers on</font> a     <font color="blue">consistent basis</font></td>
    </tr>
    <tr>
      <td>New  <font color="blue"><font color="blue">technologies</font> may</font> be developed, validated and <font color="blue">increasingly used</font> in     <font color="blue">biomedical research</font> that <font color="blue">could reduce demand</font> for some of our products and     services</td>
    </tr>
    <tr>
      <td>For many years, groups within the scientific and research <font color="blue">communities</font> have     attempted to develop models, methods and systems that would replace or     supplement  the  use  of <font color="blue">living animals as test subjects</font> in biomedical     research</td>
    </tr>
    <tr>
      <td><font color="blue">Companies </font>have developed <font color="blue">several techniques</font> that have scientific     merit</td>
    </tr>
    <tr>
      <td>It is our strategy to <font color="blue">participate</font> in some <font color="blue">fashion with</font> any non-animal     <font color="blue">test method as</font> it <font color="blue">becomes validated as</font> a research model <font color="blue">alternative</font> or     adjunct in our markets</td>
    </tr>
    <tr>
      <td>However, we may not be successful in <font color="blue">commercializing</font>     these methods if developed, and sales or <font color="blue">profits from</font> these <font color="blue">methods may</font> not     <font color="blue">offset reduced sales</font> or <font color="blue">profits from</font> <font color="blue">research models</font></td>
    </tr>
    <tr>
      <td><font color="blue">Alternative </font>research     <font color="blue">methods could decrease</font> the need for <font color="blue">research models</font>, and we may not be able     to develop new products <font color="blue">effectively</font> or in a <font color="blue">timely manner</font> to replace any     lost sales</td>
    </tr>
    <tr>
      <td>If we are not successful in selecting and <font color="blue">integrating</font> the <font color="blue">businesses</font> and     <font color="blue">technologies</font> we acquire, our business may suffer</td>
    </tr>
    <tr>
      <td>During the past five years, we have expanded our business through several     <font color="blue">acquisition</font>s</td>
    </tr>
    <tr>
      <td>We plan to continue acquire <font color="blue">businesses</font> and <font color="blue">technologies</font> and     form alliances</td>
    </tr>
    <tr>
      <td>However, <font color="blue">businesses</font> and <font color="blue"><font color="blue">technologies</font> may</font> not be <font color="blue">available on</font>     terms and <font color="blue">conditions</font> we find acceptable</td>
    </tr>
    <tr>
      <td>We <font color="blue">risk spending</font> time and money     <font color="blue">investigating</font>  and  negotiating with potential <font color="blue">acquisition</font> or alliance     partners,  but  not  completing  the  <font color="blue">transaction</font></td>
    </tr>
    <tr>
      <td>Even if completed,     <font color="blue">acquisition</font>s and <font color="blue">alliances involve numerous risks which may</font> include:       ·       <font color="blue">difficult</font>ies and <font color="blue">expenses incurred</font> in assimilating <font color="blue">operations</font>,     services, products or <font color="blue">technologies</font>;       ·       <font color="blue">difficult</font>ies in developing and operating new <font color="blue">businesses</font>, including     diversion of <font color="blue">management</font>’s attention from other business concerns;       ·       <font color="blue">potential losses</font> resulting from undiscovered <font color="blue">liabilities</font> of acquired     companies are not <font color="blue">covered by</font> the <font color="blue">indemnification</font> we may obtain from the     seller;       ·       risks of not being able to <font color="blue">overcome differences</font> in foreign business     practices, language and other <font color="blue">cultural barriers</font> in <font color="blue">connection with</font> the     <font color="blue">acquisition</font> of <font color="blue">foreign companies</font>;       ·        the  presence or absence of adequate internal controls and/or     <font color="blue">significant</font> fraud in the <font color="blue">financial systems</font> of acquired companies; and       ·       <font color="blue">difficult</font>ies in achieving business and <font color="blue">financial success</font></td>
    </tr>
    <tr>
      <td>In the event that an acquired business or <font color="blue">technology</font> or an alliance does not     <font color="blue">meet expectations</font>, our results of <font color="blue">operations</font> may be <font color="blue"><font color="blue">adversely</font> affect</font>ed</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> key personnel and may not be able to retain these employees or     recruit additional <font color="blue">qualified personnel</font>, which would harm our business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font> to a <font color="blue">significant</font> extent on the <font color="blue">continued services</font> of our     <font color="blue">senior <font color="blue">management</font></font> and other members of <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>James C Foster, our     <font color="blue">Chief Executive Officer </font>since 1992 and <font color="blue">Chairman </font>since 2000, has held various     positions  with  us for 29 years</td>
    </tr>
    <tr>
      <td>We have <font color="blue">no employment agreement with</font>     Mr</td>
    </tr>
    <tr>
      <td>Foster  or other members of our <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>Foster or other     members  of <font color="blue">management</font> do not continue in their <font color="blue">present positions</font>, our     business may suffer</td>
    </tr>
    <tr>
      <td>19     ______________________________________________________________________       Because of the <font color="blue">specialized scientific</font> nature of our business, we are highly     <font color="blue">dependent</font> upon qualified scientific, technical and <font color="blue">managerial personnel</font></td>
    </tr>
    <tr>
      <td>While we have an excellent record of employee retention, there is still     strong  <font color="blue">competition</font>  for <font color="blue">qualified personnel</font> in the <font color="blue">pharmaceutical</font> and     <font color="blue">bio<font color="blue">technology</font></font> fields</td>
    </tr>
    <tr>
      <td>Therefore, we may not be able to attract and retain     the <font color="blue">qualified personnel</font> necessary for the <font color="blue">development</font> of our business</td>
    </tr>
    <tr>
      <td>The     loss  of the services of existing personnel, as well as the failure to     recruit additional key scientific, technical and <font color="blue">managerial personnel</font> in a     <font color="blue">timely manner</font>, <font color="blue">could harm</font> our business</td>
    </tr>
    <tr>
      <td>Our quarterly operating results may vary, <font color="blue">which could</font> negatively affect the     <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our results of <font color="blue">operations</font> in any quarter may vary from quarter to quarter     and  are <font color="blue">influenced by such factors as</font> the number and scope of ongoing     customer  <font color="blue">engagements</font>,  the  commencement, postponement, completion or     <font color="blue">cancellation</font> of <font color="blue">customer contracts</font> in the quarter, changes in the mix of our     products and services, the extent of cost overruns, holiday patterns of our     customers, budget cycles of our customers, and exchange rate <font color="blue">fluctuations</font></td>
    </tr>
    <tr>
      <td>We  believe  that operating results for any <font color="blue">particular quarter</font> are not     <font color="blue">necessarily</font>  a  <font color="blue">meaningful</font>  <font color="blue">indication</font> of future results</td>
    </tr>
    <tr>
      <td>Nonetheless,     <font color="blue">fluctuations</font> in our quarterly operating results <font color="blue">could negatively affect</font> the     <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
  </tbody>
</table>